{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:28:37Z","timestamp":1750220917662,"version":"3.41.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bleeding is the most common side effect during treatment with vitamin K antagonists (VKAs). Sometimes, VKA use causes bleeding episodes due to rare variants in the factor IX (FIX) propeptide that modify the affinity of FIX propeptide to the binding of \u03b3-glutamyl carboxylase. We report on a 51-year-old patient who presented with recurrent spontaneous and severe intramuscular and cutaneous bleedings during VKA (warfarin) treatment for the presence of a prosthetic mechanical aortic valve. Laboratory evaluation revealed INR within the therapeutic range with markedly prolonged aPTT and a large reduction of FIX levels. Laboratory parameters significantly improved when warfarin was switched with low-molecular-weight heparin. Next-generation sequencing analysis revealed the variant p.(Ala37Thr) in the F9 gene, which has been previously associated with VKA sensitivity. As an alternative to warfarin, apixaban 5\u2009mg twice daily and aspirin 100\u2009mg daily were started, with no thrombosis or recurrence of hemorrhage and normalization of INR, aPTT, and FIX levels, at 12-month follow-up. We also performed a literature search across PubMed and Scopus, until January 2025. The analysis evidenced five case reports and two case series. The mechanisms of this rare VKA hypersensitivity have also been reviewed. In conclusion, while VKA hypersensitivity is a rare phenomenon, awareness of this complication and the current accessibility to molecular testing make it important to identify patients at risk. The efficacy\/safety of direct thrombin or factor Xa inhibitors in patients with a mechanical heart valve and VKA hypersensitivity due to the F9 p.(Ala37Thr) variant deserves more attention and further investigation.<\/jats:p>","DOI":"10.1055\/a-2546-7180","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:15:56Z","timestamp":1740701756000},"page":"594-599","source":"Crossref","is-referenced-by-count":1,"title":["Use of Oral Anti-Xa Inhibitor in Prosthetic Mechanical Aortic Valve with Warfarin Hypersensitivity Due to the FIX p.(Ala37Thr) Propeptide Variant: Case Report and Literature Review"],"prefix":"10.1055","volume":"51","author":[{"given":"Antonella","family":"Tufano","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Fierarossa","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Miele","sequence":"additional","affiliation":[{"name":"UOC Laboratory Medicine of Hematology and Hemostasis, Federico II University Hospital, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Capasso","sequence":"additional","affiliation":[{"name":"UOC Laboratory Medicine of Hematology and Hemostasis, Federico II University Hospital, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mazzaccara","sequence":"additional","affiliation":[{"name":"UOC Laboratory Medicine of Hematology and Hemostasis, Federico II University Hospital, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Micale","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Vecchione","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Castori","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Frangipane","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Mocerino","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Cimino","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Di Minno","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"47","key":"ref1","doi-asserted-by":"crossref","first-page":"15681","DOI":"10.1021\/bi991544k","article-title":"Amino acids responsible for reduced affinities of vitamin K-dependent propeptides for the carboxylase","volume":"38","author":"T B Stanley","year":"1999","journal-title":"Biochemistry"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4065\/mcp.2009.0278","article-title":"Warfarin sensitivity genotyping: a review of the literature and summary of patient experience","volume":"84","author":"T P Moyer","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2003-09-3043","article-title":"Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity","volume":"103","author":"E Shikata","year":"2004","journal-title":"Blood"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/GIM.0b013e318163c35f","article-title":"Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin","volume":"10","author":"D A Flockhart","year":"2008","journal-title":"Genet Med"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cll.2008.09.001","article-title":"Pharmacogenetic testing for warfarin sensitivity","volume":"28","author":"E Lyon","year":"2008","journal-title":"Clin Lab Med"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"e911","DOI":"10.1097\/MJT.0000000000000077","article-title":"The conundrum of \u201cwarfarin hypersensitivity\u201d: prolonged partial thromboplastin time from factor IX propeptide mutation","volume":"23","author":"A Sekhri","year":"2016","journal-title":"Am J Ther"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00277-018-3398-2","article-title":"Major bleeding in a patient with warfarin-hypersensitive and factor IX propeptide variant, p.Ala37Thr, who was treated with a direct oral anti-Xa inhibitor","volume":"98","author":"A Tamura","year":"2019","journal-title":"Ann Hematol"},{"issue":"08","key":"ref9","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.3324\/haematol.2019.229047","article-title":"Vitamin K-dependent carboxylation of coagulation factors: insights from a cell-based functional study","volume":"105","author":"Z Hao","year":"2020","journal-title":"Haematologica"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1172\/JCI118956","article-title":"A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism","volume":"98","author":"K Chu","year":"1996","journal-title":"J Clin Invest"},{"issue":"23","key":"ref11","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.1073\/pnas.84.23.8335","article-title":"Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase","volume":"84","author":"P A Price","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"ref12","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1021\/bi00396a022","article-title":"Propeptide of human protein C is necessary for gamma-carboxylation","volume":"26","author":"D C Foster","year":"1987","journal-title":"Biochemistry"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-2141.1997.2213036.x","article-title":"Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy","volume":"98","author":"J Oldenburg","year":"1997","journal-title":"Br J Haematol"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00277-018-3264-2","article-title":"Variants in FIX propeptide associated with vitamin K antagonist hypersensitivity: functional analysis and additional data confirming the common founder mutations","volume":"97","author":"B Pezeshkpoor","year":"2018","journal-title":"Ann Hematol"},{"key":"ref15","first-page":"100","article-title":"Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland","volume":"138","author":"S Ulrich","year":"2008","journal-title":"Swiss Med Wkly"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/s-0037-1615604","article-title":"Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10)","volume":"85","author":"J Oldenburg","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.thromres.2018.12.005","article-title":"Severe bleeding due to hypersensitivity to vitamin K antagonist caused by the c.109G>A (p.Ala37Thr) mutation in the F9 gene in a patient with mechanical heart valve prosthesis","volume":"174","author":"E Odnoczko","year":"2019","journal-title":"Thromb Res"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","article-title":"When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review","volume":"83","author":"A Bejjani","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"J W Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical on-X aortic heart valve","volume":"227","author":"O K Jawitz","year":"2020","journal-title":"Am Heart J"},{"issue":"07","key":"ref21","first-page":"a2300067","article-title":"Apixaban or warfarin in patients with an on-X mechanical aortic valve","volume":"2","author":"T Y Wang","year":"2023","journal-title":"NEJM Evid"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2020.11.035","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"77","author":"C M Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"ref23","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"I C Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-pharmtox-032823-122811","article-title":"Oral anticoagulants beyond warfarin","volume":"64","author":"R H Olie","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0043-1777827","article-title":"Outcomes of patients with a mechanical heart valve and poor anticoagulation control on warfarin","volume":"124","author":"I Johansson","year":"2024","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1182\/blood-2002-06-1753","article-title":"Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity","volume":"100","author":"S R Kristensen","year":"2002","journal-title":"Blood"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.1365-2141.2000.01901.x","article-title":"Ala-10 mutations in the factor IX propeptide and haemorrhage in a patient treated with warfarin","volume":"108","author":"P Baker","year":"2000","journal-title":"Br J Haematol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2546-7180.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:52:48Z","timestamp":1750204368000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2546-7180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":26,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2546-7180","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"type":"print","value":"0094-6176"},{"type":"electronic","value":"1098-9064"}],"subject":[],"published-other":{"date-parts":[[2025,2,27]]},"published":{"date-parts":[[2025,2,27]]}}}